

# GI and Liver Disorders I Panel

---

## Series Editors:

### **Bradley A. Boucher, Pharm.D., FCCP, FNAP, MCCM, BCPS**

*Professor of Clinical Pharmacy and Translational Science  
Associate Dean for Strategic Initiatives and Operations  
College of Pharmacy  
University of Tennessee Health Science Center  
Memphis, Tennessee*

### **Curtis E. Haas, Pharm.D., FCCP**

*Director of Pharmacy  
University of Rochester Medical Center  
Rochester, New York*

### **Jane M. Gervasio, Pharm.D., FCCP, BCNSP**

*Chair  
Professor of Pharmacy Practice  
Department of Pharmacy Practice  
College of Pharmacy and Health Sciences  
Butler University  
Indianapolis, Indiana*

## GI Alterations

### Author

#### **Sean P. Kane, Pharm.D., BCPS**

*Assistant Professor  
Department of Pharmacy Practice  
Rosalind Franklin University of Medicine and Science  
North Chicago, Illinois  
Critical Care Pharmacist  
Pharmacy Department  
Advocate Condell Medical Center  
Libertyville, Illinois*

### Reviewers

#### **Divya Merry Daniel, Pharm.D., BCCCP**

*Trauma Pharmacy Clinical Coordinator  
Department of Pharmacy  
St. David's South Austin Medical Center  
Austin, Texas*

#### **Carol Heunisch, Pharm.D., BCPS**

*Director, Inpatient Pharmacy Services  
Department of Pharmacy  
NorthShore University HealthSystem  
Evanston, Illinois*

#### **Shereen Ahmed Dasuqi, MSc Pharm, BCPS, BCCCP**

*Critical Care Clinical Pharmacist  
Clinical Pharmacy Residency Program Coordinator  
King Saud University Medical City  
Riyadh, Saudi Arabia*

## Acute Liver Failure

### Author

#### **Dustin D. Linn, Pharm.D., BCPS, BCCCP**

*Associate Professor of Pharmacy Practice  
Department of Pharmacy Practice  
Manchester University College of Pharmacy,  
Natural, & Health Sciences  
Critical Care Clinical Pharmacy Specialist  
Department of Pharmacy  
Parkview Regional Medical Center  
Fort Wayne, Indiana*

### Reviewers

#### **Gerald J. Rebo, Pharm.D., BCPS, BCCCP, CPP**

*Pharmacist Team Leader, Surgery and Neurosciences  
Pharmacy Department  
Wake Forest Baptist Health  
Winston-Salem, North Carolina*

#### **Russel J. Roberts, Pharm.D., BCCCP**

*Clinical Pharmacy Manager - Cardiology,  
Critical Care, and Infectious Diseases  
Department of Pharmacy  
Massachusetts General Hospital  
Boston, Massachusetts*

#### **Sheela Shneezai, Pharm.D., BCCCP, BCGP**

*Clinical Pharmacy Specialist  
Antelope Valley Hospital  
Lancaster, California*

## Severe Acute Pancreatitis

### Authors

#### **Jennifer McCann, Pharm.D., BCCCP**

*Assistant Professor for Pharmacy Practice  
College of Pharmacy and Health Sciences  
Butler University  
Clinical Pharmacy Specialist – Infectious Disease  
Franciscan Alliance Indianapolis Hospital  
Indianapolis, Indiana*

#### **Sarah D. Hittle, Pharm.D., BCCCP**

*Clinical Specialist – Medical ICU  
Critical Care Co-preceptor  
St. Vincent Indianapolis Hospital  
Indianapolis, Indiana*

## Reviewers

### **Christopher A. Anderson, Pharm.D., BCPS**

*Clinical Pharmacy Specialist: Surgical ICU*  
Pharmacy Department  
Indiana University Health: University Hospital  
Indianapolis, Indiana

### **Oussayma Moukhachen, Pharm.D., BCPS**

*Associate Professor of Pharmacy Practice*  
Department of Pharmacy Practice  
School of Pharmacy  
MCPHS University  
Boston, Massachusetts

### **Laura A. Siemianowski, Pharm.D., BCPS, BCCP**

*Clinical Pharmacy Specialist, Medical Critical Care*  
Department of Pharmacy  
Hospital of the University of Pennsylvania  
Philadelphia, Pennsylvania

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the GI and Liver Disorders I chapters:

### **Lynn Kassel, Pharm.D., BCPS**

*Assistant Professor*  
Department of Clinical Sciences  
Drake University College of Pharmacy & Health Sciences  
Des Moines, Iowa  
*Acute Care Pharmacist*  
Mercy West Lakes Hospital  
Clive, Iowa

### **Jeffrey T. Sherer, Pharm.D., MPH, BCPS, BCGP**

*Clinical Associate Professor*  
Department of Pharmacy Practice  
and Translational Research  
University of Houston College of Pharmacy  
Houston, Texas

## DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** Sheela Shneezai (Biok)

**Stock Ownership:** Jodi A. Dreiling (Theravance Biopharma)

**Royalties:**

**Grants:** Ohoud A. Aljuhani (King Abdulaziz University); Michael Kenes (National Center for Advancing Translational Science)

**Honoraria:** John M. Allen (Abbott Nutrition); Sheela Shneezai (Kabul University [Afghanistan])

**Other:** Jodi A. Dreiling (employed by Theravance Biopharma); Karen Hamrick Samaan (employed by Lilly)

**Nothing to disclose:** Christopher A. Anderson; Abigail D. Antigua; Suzanne Benjamin; Sara E. Bliss; Sarah Vest Cogle; Shereen Ahmed Dasuqi; Divya Merry Daniel; Serena A. Harris; Carol Heunisch; Sarah D. Hittle; Sean P. Kane; Dustin Linn; Edward Scott Lozano; Jennifer McCann; Michael J. McQuade; Oussayma Moukhachen; Gerald J. Rebo; Russel J. Roberts; Karen Samaan; Laura A. Siemianowski; Craig B. Whitman

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. CCSAP has been approved by BPS for use in BCCCP recertification. Information about the BPS recertification process is available [online](#).

Questions regarding BCCCP recertification should be directed to:

[Board of Pharmacy Specialties](#)  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591